Omnipod GO will expand our addressable market by at least 3 million people in the U.S. alone who require basal-only insulin. We look forward to the key learnings from our pilot program, which will help inform our full market release in 2024. We are very well positioned in the type 2 market to grow adoption with Omnipod DASH and, soon, Omnipod GO, not to mention an expected future type 2 indication for Omnipod 5. We certainly have a number of competitive advantages in this space, including our differentiated form factor, an affordable pay-as-you-go business model and a pharmacy channel access. As a result, we continue to add a substantial number of type 2 patients to our customer base. During Q2, people with type 2 diabetes represented an estimated 20% of our U.S. new customer starts across our Omnipod portfolio of products.